Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin Plus Lapatinib in HER2-positive Metastatic Breast Cancer (E-VITA)
NCT01534455Phase 2Terminated
- Sponsor
- GBG Forschungs
- Start
- Feb 2012
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in breast cancer, sponsored by GBG Forschungs. Started Feb 2012; status: terminated.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01534455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01534455.